Debiopharm Group (Debiopharm) and Ipsen have reported that the 6-month sustained-release formulation of Decapeptyl (triptorelin embonate 22.5mg) has successfully completed its European decentralised registration procedure involving nine countries:
Alkermes has reported positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system
Nobilon, the human vaccine business unit of Schering-Plough has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for
Sinovac Biotech (Sinovac) has reported that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) has received the Certificate of Approval to distribute Panflu (H5N1), its H5N1 (bird flu) pandemic
Dyax has unveiled new developments involving drug candidates identified using the company’s phage display technology as a result of two deals recently announced by sanofi-aventis. Sanofi-aventis is planning
Compugen has signed a collaboration agreement with Bayer Schering Pharma (Bayer), covering the further evaluation of a Compugen discovered tumor target and its splice variants. Following an initial
International Stem Cell has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology.
Metabolex, a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, reported positive results from two multiple ascending dose
Perrigo Company (Perrigo) has filed an Abbreviated New Drug Application (ANDA) for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of Men’s Rogaine Foam. Men’s Rogaine
MeadWestvaco (MWV) has completed a year-long validation and industrialisation capital program for its line of preservative-free nasal pumps, the PFP N. It is available in outputs ranging from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.